Evidence map›Paper›PMID 36515702›Full record

ArticleJournal of neurology2023

Genotype-phenotype characterisation of long survivors with motor neuron disease in Scotland.

Danielle J Leighton, Morad Ansari, Judith Newton, David Parry, Elaine Cleary, Shuna Colville, Laura Stephenson, Juan Larraz, Micheala Johnson, Emily Beswick and 16 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 11 institutions in 1 country.

Danielle J LeightonSchool of Psychology & Neuroscience, University of Glasgow, Glasgow, UK. Danielle.leighton@glasgow.ac.uk.ORCID http://orcid.org/0000-0003-2015-7198
Morad AnsariSouth East Scotland Genetics Service, Western General Hospital, Edinburgh, UK.
Judith NewtonEuan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.
David ParryCentre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Elaine ClearySouth East Scotland Genetics Service, Western General Hospital, Edinburgh, UK.
Shuna ColvilleEuan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.
Laura StephensonEuan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.
Juan LarrazAnne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.
Micheala JohnsonAnne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.
Emily BeswickAnne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.
Michael WongAnne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.
Jenna GregoryEuan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.
Javier Carod ArtalDepartment of Neurology, NHS Highland, Inverness, UK.
Richard DavenportEuan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.
Callum DuncanDepartment of Neurology, Aberdeen Royal Infirmary, Aberdeen, UK.
Ian MorrisonDepartment of Neurology, NHS Tayside, Dundee, UK.
Colin SmithEuan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.
Robert SwinglerEuan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.
Ian J DearyLothian Birth Cohorts Group, Department of Psychology, University of Edinburgh, Edinburgh, UK.
Mary PorteousSouth East Scotland Genetics Service, Western General Hospital, Edinburgh, UK.
Timothy J AitmanCentre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Siddharthan ChandranEuan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.
George H GorrieEuan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.
Suvankar PalEuan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.
Lothian Birth Cohorts Group
and the CARE-MND Consortium
Edinburgh Royal Infirmary · GBEdinburgh Cancer Research · GBNHS Lothian · GBUniversity of Edinburgh · GBWestern General Hospital · GBAberdeen Royal Infirmary · GBMott MacDonald (United Kingdom) · GBNHS Highland · GBNHS Tayside · GBQueen Elizabeth University Hospital · GBUniversity of Aberdeen · GB

Funding

Chief Scientist Office SGP/1Chief Scientist Office SGP/2Medical Research Council MC_EX_MR/N50192X/1Medical Research Council MC_PC_15080Medical Research Council MR/K026992/1
6 · The paper itself

Abstract

backgroundWe investigated the phenotypes and genotypes of a cohort of 'long-surviving' individuals with motor neuron disease (MND) to identify potential targets for prognostication.

methodsPatients were recruited via the Clinical Audit Research and Evaluation for MND (CARE-MND) platform, which hosts the Scottish MND Register. Long survival was defined as > 8 years from diagnosis. 11 phenotypic variables were analysed. Whole genome sequencing (WGS) was performed and variants within 49 MND-associated genes examined. Each individual was screened for C9orf72 repeat expansions. Data from ancestry-matched Scottish populations (the Lothian Birth Cohorts) were used as controls.

results58 long survivors were identified. Median survival from diagnosis was 15.5 years. Long survivors were significantly younger at onset and diagnosis than incident patients and had a significantly longer diagnostic delay. 42% had the MND subtype of primary lateral sclerosis (PLS). WGS was performed in 46 individuals: 14 (30.4%) had a potentially pathogenic variant. 4 carried the known SOD1 p.(Ile114Thr) variant. Significant variants in FIG4, hnRNPA2B1, SETX, SQSTM1, TAF15, and VAPB were detected. 2 individuals had a variant in the SPAST gene suggesting phenotypic overlap with hereditary spastic paraplegia (HSP). No long survivors had pathogenic C9orf72 repeat expansions.

conclusionsLong survivors are characterised by younger age at onset, increased prevalence of PLS and longer diagnostic delay. Genetic analysis in this cohort has improved our understanding of the phenotypes associated with the SOD1 variant p.(Ile114Thr). Our findings confirm that pathogenic expansion of C9orf72 is likely a poor prognostic marker. Genetic screening using targeted MND and/or HSP panels should be considered in those with long survival, or early-onset slowly progressive disease, to improve diagnostic accuracy and aid prognostication.

Indexed as

Amyotrophic Lateral SclerosisMotor Neuron DiseaseSpastic Paraplegia, HereditaryC9orf72 ProteinDelayed DiagnosisDNA HelicasesFlavoproteinsGenotypeHumansMultifunctional EnzymesPhenotypePhosphoric Monoester HydrolasesRNA HelicasesSpastinSuperoxide Dismutase-1C9orf72 ProteinDNA HelicasesFIG4 protein, humanFlavoproteinsMultifunctional EnzymesPhosphoric Monoester HydrolasesRNA HelicasesSETX protein, humanSpastinSPAST protein, humanSuperoxide Dismutase-1Amyotrophic lateral sclerosisGeneticsMotor neuron diseaseSurvival

Identifiers

PMID36515702
PMCPMC9971124
OpenAlexW4311393077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.